Alert detail
LCD L39467: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — Noridian
What changed
Who’s affected: Rheumatology billing teams · Effective: January 22, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 6 billing codes.
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Audit documentation
Building an audit file?
The Tripwire Audit Pack exports 12 months of Rheumatology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Not ready to subscribe?
Get the free weekly reimbursement brief for Rheumatology— the week’s changes and deadlines, delivered to your inbox. No account required.